Inactive Instrument

ViaDerma, Inc. Stock price Other OTC

Equities

VDRM

US92555K1016

Biotechnology & Medical Research

Sales 2015 192K Sales 2016 252K Capitalization 618K
Net income 2015 - Net income 2016 - EV / Sales 2015 1.5 x
Net Debt 2015 288K Net Debt 2016 297K EV / Sales 2016 3.63 x
P/E ratio 2015
10.7 x
P/E ratio 2016
-3.3 x
Employees -
Yield 2015 *
-
Yield 2016
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
ViaDerma, Inc. Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product CI
ViaDerma Announces Intent to Launch New Minoxidil Hair Regrowth Product CI
ViaDerma, Inc. Successfully Completes Quality Control Testing of Its New Vitastem Products CI
ViaDerma, Inc. Set to Launch Two New and Improved Versions of Its Flagship Product, Vitastem and Vitastem Ultra CI
ViaDerma, Inc. Provides Updates on Current Business Activities CI
ViaDerma, Inc. Announces Expansion of Its Current Licensing Agreement CI
ViaDerma, Inc. Nearing Initial Order from Large Hospital Network CI
ViaDerma, Inc. Provides Revenue Guidance for the First Quarter of 2021 CI
ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States CI
ViaDerma, Inc. Enters into A $250,000 Initial Sales Agreement with Vage Nigeria Ltd CI
ViaDerma, Inc. Grants Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products CI
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx CI
ViaDerma, Inc. Receives National Drug Code from the FDA for Prolayed CI
Viaderma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and Development of New Products with its MMJ Technologies CI
Viaderma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration for New OTC Drug to Conquer Premature Ejaculation for Men CI
More news
Managers TitleAgeSince
Chief Executive Officer - 14-03-30
Members of the board TitleAgeSince
Chief Executive Officer - 14-03-30
More insiders
ViaDerma, Inc. is a specialty pharmaceutical company engaged in bringing new products to market and licensing its transdermal drug delivery technology solutions. The Company’s lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. In addition to licensing its proprietary transdermal technologies, its lead product, Vitastem, is available for treating multiple skin conditions and ailments. The Company also has products in development in fields, such as anti-aging skin care, pain management, hair-loss, and toenail fungus. The products are based on a delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The Company’s products are sold to local medical practitioners and patients in clinics primarily in the Los Angeles, California area. The Company’s subsidiary is ViaDerma, II Inc.
More about the company
  1. Stock
  2. Equities
  3. Stock ViaDerma, Inc.
  4. Stock ViaDerma, Inc. - Other OTC